

# TIM3, a human acute myeloid leukemia stem cell marker, does not enrich for leukemia-initiating stem cells in B-cell acute lymphoblastic leukemia

Clara Bueno,<sup>1,2,3</sup> Alba Martínez,<sup>1,2</sup> Paola Alejandra Romecin,<sup>1,2</sup> Samanta Romina Zanetti,<sup>1</sup> Ricky Tirtakusuma,<sup>4</sup> Eulalia Genesca,<sup>1</sup> Mireia Camós,<sup>5,6</sup> Manuel Ramírez-Orellana,<sup>2,7</sup> Eduardo Anguita,<sup>8</sup> Paola Ballerini,<sup>9</sup> Franco Locatelli,<sup>10</sup> José Luis Fuster<sup>11</sup> and Pablo Menéndez<sup>1,2,3,12,13</sup>

<sup>1</sup>Josep Carreras Leukemia Research Institute, Barcelona, Spain; <sup>2</sup>Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid, Spain; <sup>3</sup>CIBER-ONC, ISCIII, Barcelona, Spain; <sup>4</sup>Newcastle University, Newcastle upon Tyne, UK; <sup>5</sup>Hematology Laboratory, Hospital Sant Joan de Déu, Barcelona, Spain; <sup>6</sup>Leukemia and other Pediatric Hemopathies, Developmental Tumor Biology Group, Institutut de Recerca Hospital Sant Joan de Déu, Barcelona, Spain; <sup>7</sup>Oncohematología, Hospital Niño Jesús, Madrid, Spain; <sup>8</sup>Servicio de Hematología, Hospital Clínico San Carlos, IDISSC, Medicina UCM, Madrid, Spain; <sup>9</sup>Pediatric Hematology, Armand Trousseau Hospital, Paris, France; <sup>10</sup>Department of Hematology and Oncology, Ospedale Bambino Gesú, Rome, Italy; <sup>11</sup>Sección de Oncohematología Pediátrica, Hospital Clínico Universitario Virgen de la Arrixaca and Instituto Murciano de Investigación Biosanitaria (IMIB), El Palmar, Murcia, Spain; <sup>12</sup>Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain and <sup>13</sup>Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain

Correspondence:

P. MENENDEZ - pmenendez@carrerasresearch.org

C. BUENO - cbueno@carrerasresearch.org

<https://doi.org/10.3324/haematol.2022.282394>

**Table S1:** Characteristics of B-ALL patients analyzed in this study

|                        | Total Nº of patients | Age       |
|------------------------|----------------------|-----------|
| <b>Pediatric B-ALL</b> |                      |           |
| <i>Diagnosis</i>       | 32                   |           |
| Hyperdiploid           | 6                    | 5.5±1.6   |
| ETV6-RUNX1             | 10                   | 4.9±1.1   |
| iAmp21                 | 3                    | 7.8±2.7   |
| KMT2A-r                | 5                    | 0.8±0.1   |
| E2A-PBX1               | 1                    | 9         |
| B-other                | 6                    | 9.0±2.7   |
| NA*                    | 1                    | -         |
| <i>Relapse</i>         | 25                   |           |
| Hyperdiploid           | 2                    | 9.3±4.3   |
| ETV6-RUNX1             | 1                    | 5.5       |
| iAmp21                 | 3                    | 11.2±2.9  |
| KMT2A-r                | 2                    | 4.5±0.5   |
| E2A-PBX1               | 6                    | 15.6±1.9  |
| B-other                | 1                    | 3         |
| NA                     | 10                   | -         |
| <b>Adult B-ALL</b>     |                      |           |
| <i>Diagnosis</i>       | 15                   |           |
| BCR-ABL1+              | 3                    | 41.7±5.0  |
| BCR-ABL1-              | 10                   | 39.1±6.0  |
| NA                     | 2                    | 22.5±0.5  |
| <i>Relapse</i>         | 13                   |           |
| BCR-ABL1-              | 11                   | 39.6±5.4  |
| NA                     | 2                    | 43.5±10.5 |

\*NA: Non available